New Daily Pill May Prevent Weight Regain After Discontinuing Obesity Injections
Recent research suggests that a new daily medication could help individuals maintain their weight loss after they stop using obesity-treatment injections. This development addresses a significant challenge in weight management, as patients often face the risk of regaining weight once they cease using GLP-1 injections.
The medication, known as orforglipron, was evaluated in trials where patients took the pill daily for one year. The results indicated that those using the drug were able to avoid regaining a substantial portion of the weight they had previously lost. This finding is particularly relevant for public health, as it offers a potential strategy for long-term weight maintenance beyond the initial injection phase.
The study was published in the journal Nature Medicine and was funded by Eli Lilly. The pharmaceutical company, which also produces the weight-loss injection Mounjaro, is the manufacturer of orforglipron.
Experts suggest that the administration method could significantly improve patient adherence. Dr. Mary Sprekli, a weight management research expert at the University of Cambridge who was not involved in the study, noted that taking a pill may be a more attractive option for many patients than the requirement of self-injecting.
While orforglipron is already available in the United States, it may be launched in the United Kingdom in the near future. Despite the promising results, researchers emphasize that further study is required to determine the necessary duration of treatment, noting that some patients may potentially need to continue the medication for the rest of their lives.
